Therapy Areas: Vaccines
ReViral Ltd Names Hetherington as Chief Medical Officer
27 February 2019 - - UK-based anti-viral compounds developer ReViral Ltd has appointed Seth Hetherington, MD as chief medical officer, the company said.

Hetherington, who will be based in the US, brings to ReViral more than three decades of clinical, regulatory and industry experience in developing treatments for clinically important viral infections.

He joins ReViral from Genocea Biosciences Inc. (NASDAQ: GNCA), where he was chief medical officer for seven years, leading the clinical development of therapeutic vaccines, including for certain viral targets.

Prior to Genocea, he served as senior vice president, clinical and regulatory affairs at Icagen, Inc. and vice president, clinical development and chief medical officer at Inhibitex, Inc.

His previous industry experience includes clinical drug development at GlaxoSmithKline, where he made significant contributions to several clinical development programs, including the currently marketed anti-viral pharmaceuticals, Ziagen, Trizivir and Agenerase.

Hetherington is an adjunct clinical faculty member at the University of North Carolina School of Medicine and previously held academic appointments at the University of Tennessee, St. Jude Children's Research Hospital in Memphis and Albany Medical College.

ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus.

Founded in 2011, ReViral has an experienced R and D leadership team with a successful track record in antiviral drug discovery and development.

The company has developed a novel antiviral programme targeting RSV fusion with highly potent, orally bioavailable inhibitors, strong drug-like characteristics and good pharmacokinetic properties offering versatility in route of administration.

The lead candidate RV521 completed a Phase IIa study in adult volunteers showing high potency and excellent safety. The company also has an RSV replication programme at an earlier stage of development and plans to expand its pipeline.

In August 2018, ReViral completed a USD 55m series B funding round from a group of venture capital investors jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings A/S, with additional new investment from Perceptive Advisors.
Login
Username:

Password: